Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.
Status:
Withdrawn
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
This is an open label, non randomized, prospective, multicenter, phase II clinical trial
evaluating nilotinib 400 mg BID for the treatment of newly diagnosed CML-AP patients.
Patients enrolled into the study will receive 400mg of nilotinib, orally, twice daily
(800mg/day)